D-Arabitol

Synonyms: D-阿拉伯糖醇
D-Arabitol 是一种口服有效的阿拉伯糖醇 D-型对映异构体,可调节肠道菌群组成、增加短链脂肪酸并促进 AMPK-PGC-1α 相关的白色脂肪组织褐变,从而改善体重增加、脂肪堆积、胰岛素抵抗、脂质沉积及炎症反应,同时可作为 Bacillus methanolicus MGA3 的唯一碳/能量来源(该菌株可将其与甘露醇共同利用),并可用于肥胖相关研究。
产品编号: MS-W71937 纯度: 99.92% CAS No.: 488-82-4 分子式: C5H12O5 分子量: 152.15
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
3-5 天
> 100g
询价
询价

产品描述

D-Arabitol 是一种口服有效的阿拉伯糖醇 D-型对映异构体,可调节肠道菌群组成、增加短链脂肪酸并促进 AMPK-PGC-1α 相关的白色脂肪组织褐变,从而改善体重增加、脂肪堆积、胰岛素抵抗、脂质沉积及炎症反应,同时可作为 Bacillus methanolicus MGA3 的唯一碳/能量来源(该菌株可将其与甘露醇共同利用),并可用于肥胖相关研究。

生物实验数据

生物活性 D-Arabitol is an orally active D-enantiomer of arabitol that modulates gut microbiota composition, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue, thereby ameliorating body weight gain, fat accumulation, insulin resistance, lipid deposition, and inflammatory responses; it can also serve as the sole carbon/energy source for Bacillus methanolicus MGA3, which can co-utilize it with mannitol, and is applicable to obesity-related research.
IC50 & Target

Microbial Metabolite

 

Human Endogenous Metabolite

 

体外研究
(In Vitro)

D-arabitol (10-60 mM) 可作为唯一碳源支持 Bacillus methanolicus MGA3 生长,且在等摩尔混合物中可与甘露醇共消耗。
D-arabitol (15 mM; 孵育至 OD600 = 1.0) 可显著上调 Bacillus methanolicus MGA3 中的 atlABCD 基因簇,且在与甘露醇共利用的条件下,atlD 的转录水平也会升高。
D-arabitol (30 mM) 可单独实现 Bacillus methanolicus MGA3 的 atlD 基因或完整 atlABCD 基因簇的异源表达,从而恢复阿拉伯糖醇缺陷型 Corynebacterium glutamicum ΔmtlD 的生长。
D-arabitol (15 mM; 孵育至 OD600 = 1.0) 可在 Bacillus methanolicus MGA3 的粗细胞提取物中诱导升高的阿拉伯糖醇磷酸脱氢酶活性 (0.05 U/mg),该酶对木酮糖 5-磷酸具有高亲和力 (Km = 0.03 mM)。

Real Time qPCR

Cell Line: Bacillus methanolicus MGA3
Concentration: 15 mM (RNA-seq, sole carbon source); 15 mM (RNA-seq, mannitol control); 15 mM (qRT-PCR, D-arabitol plus 15 mM mannitol)
Incubation Time: growth to mid-exponential phase (OD600 = 1.0)
Result: Induced significant upregulation of the atlA (log2 fold change = 3.06), atlB (log2 fold change = 3.41), atlC (log2 fold change = 2.73), and atlD (log2 fold change = 2.90) gene cluster when used as a 15 mM sole carbon source compared to 15 mM mannitol.
Showed elevated atlD transcript levels in cells grown on 15 mM D-arabitol plus 15 mM mannitol compared to mannitol alone, as confirmed by qRT-PCR.
体内研究
(In Vivo)

D-Arabitol (4-8%;膳食补充;每日;10 周) 可呈剂量依赖性改善雄性 SD 大鼠中高脂饮食 (HFD) 诱导的肥胖、胰岛素抵抗、脂质沉积及炎症反应,其作用机制为调节肠道菌群、增加 SCFA 生成,并通过 AMPK-PGC-1α 通路促进 WAT 褐变。

Animal Model: Sprague-Dawley (SD) (male, 180 g)
Dosage: 4% (dietary supplementation); 8% (dietary supplementation)
Administration: dietary supplementation; daily; 10 weeks
Result: Significantly reduced HFD-induced body weight gain, liver weight, epididymal fat weight, and Lee's index, with 8% D-Arabitol showing a greater reduction than 4%.
Reduced HFD-induced fasting glucose by 28.17% (8% dose).
Significantly decreased the HOMA-IR index and increased the QUICK index and serum adiponectin levels (both doses).
Dose-dependently reduced serum total cholesterol (TC), triacylglycerols (TG), low-density lipoprotein cholesterol (LDL-C), and hepatic TC and TG, while increasing serum high-density lipoprotein cholesterol (HDL-C) and reducing serum leptin, with 8% D-Arabitol showing more significant lipid-lowering effects than 4%.
Significantly reduced HFD-increased serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and reduced hepatic lipid droplet accumulation (8% dose).
Dose-dependently reduced serum levels of proinflammatory cytokines C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and decreased relative mRNA expression of proinflammatory cytokines IL-6, TNF-α, interleukin-1β (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) in epididymal adipose tissue, while increasing anti-inflammatory cytokine interleukin-10 (IL-10) mRNA expression (both doses).
Significantly increased fecal concentrations of propionic acid, butyric acid, isovaleric acid, and total short-chain fatty acids (SCFAs) compared to the HFD group (8% dose).
Upregulated relative mRNA expression of white adipose tissue (WAT) browning-related genes PPAR-γ, Cidea, Prdm16, PGC-1α, and UCP-1 in epididymal adipose tissue, and increased protein expression of AMPK, p-AMPK, and PPAR-γ (8% dose).
性状 固体
颜色 White to off-white

化学信息

分子量 152.15
分子式 C5H12O5
CAS No. 488-82-4
别名 D-阿拉伯糖醇

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (13.14 mM), Sonication is recommended.
10% DMSO+90% Saline: 10 mg/mL (65.72 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 66.67 mg/mL (438.19 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM6.5725 mL32.8623 mL65.7246 mL164.3115 mL
5 mM1.3145 mL6.5725 mL13.1449 mL32.8623 mL
10 mM0.6572 mL3.2862 mL6.5725 mL16.4312 mL
15 mM0.4382 mL2.1908 mL4.3816 mL10.9541 mL
20 mM0.3286 mL1.6431 mL3.2862 mL8.2156 mL
25 mM0.2629 mL1.3145 mL2.6290 mL6.5725 mL
30 mM0.2191 mL1.0954 mL2.1908 mL5.4771 mL
40 mM0.1643 mL0.8216 mL1.6431 mL4.1078 mL
50 mM0.1314 mL0.6572 mL1.3145 mL3.2862 mL
60 mM0.1095 mL0.5477 mL1.0954 mL2.7385 mL
80 mM0.0822 mL0.4108 mL0.8216 mL2.0539 mL
100 mM0.0657 mL0.3286 mL0.6572 mL1.6431 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础